The stubborn placebo: Finding hope amid the turmoil over AMT-130

Last October, I wrote about a potential gene therapy for Huntington’s disease, an illness my family is very familiar with, as my wife, Jill, and daughter, Alexus, are both gene-positive.

The experimental treatment is called AMT-130. According to uniQure, the therapy’s developer, top-line data from two Phase 1/2 clinical trials showed that it slowed Huntington’s progression by 75% after three years.

Jill and I were hopeful but concerned about potential issues regarding study sample sizes, neurosurgical demands, cost, and equitable access.

Recommended Reading

March 10, 2026 News by Michela Luciano, PhD

Genetic burden similar, but HD’s social impact hits women harder

Steering into a gathering storm

Recent news regarding uniQure made us realize that, every time there’s word of a potential treatment for Huntington’s, we feel as if we’re in a leaking boat watching a storm gather on the horizon.

The news I am alluding to is that the U.S. Food and Drug Administration (FDA) doesn’t believe uniQure’s study data provide sufficient evidence that AMT-130 offers clinical benefit for people with Huntington’s, so the agency can’t approve the therapy. The FDA is asking uniQure to run another study to prove that its gene therapy “actually helps people with Huntington’s disease.” UniQure has pushed back, saying the agency’s recent statements to the press were “incomplete or entirely incorrect.” For regulators to criticize a drug still under review is unusual, which only intensified the public drama.

From the outside, this might sound like a story about corporate behavior and government oversight. From where my wife, daughter, and I sit, it feels more like watching an already fragile boat heading toward a hurricane. This kind of conflict between regulators and pharmaceutical companies makes the waves rise higher for families like mine, who are already bailing water as fast as we can.

Huntington’s disease isn’t just a headline

We live with Huntington’s every day, so we do not read these stories as headlines; we read them as hints about our future. The Huntington’s disease community pins its hopes on every serious therapeutic attempt, especially on something as ambitious as gene therapy.

When the headlines focus on allegations and finger-pointing, the human stakes vanish, even though we are the ones who will pay the price if the turmoil delays, or derails, progress.

I have always been cautious about getting swept up in excitement around any experimental therapy, no matter how promising the science looks. Success in a handful of patients is not everything, but it is something, a signal that maybe the approach has promise and deserves to be tested carefully and transparently.

Jill has talked openly about her fears of a 12-to-18-hour brain surgery and the complications that could come from it. The idea of her on an operating table for that long, with all the unknowns that surround such a procedure, keeps me up some nights.

In many communities, the mere length and risk of a surgery like that might hinder study enrollment. But that is not how Huntington’s families tend to react. Jill and I have heard others affected by Huntington’s say they would willingly risk their lives for the sake of future generations, if that is what it took. This is the kind of love and desperation that fuels our community.

A placebo against despair

Yet I also know this: No one gets into rare disease research because it is a quick path to wealth. You only stay in that game if you truly believe in the science and are willing to keep going despite the setbacks.

That is why this public clash between regulators and uniQure feels so painful. I do not believe that researchers, clinicians, or the people guiding these programs wake up in the morning thinking only about profits. They see patients. They know that each day without a treatment is another day of decline, another moment when a family wonders how much longer their loved one will remember their name.

So when oversight turns into open warfare in the press, the collateral damage lands squarely on families who can least afford more uncertainty.

My cautiousness remains. I still believe it is dangerous to oversell any early findings, especially when data are limited. But I also recognize that, even if this particular gene therapy isn’t successful, it is still worth pursuing. Every attempt that reaches real patients teaches scientists more about dosing, safety, trial design, and how this disease responds to intervention. Even a failure can move the ball down the field, giving the next team better field position.

This hopefulness is a kind of stubborn placebo. We refuse to let despair have the last word.

Still, living with Huntington’s feels like spending your life in that leaking boat. Each time a trial ends without clear success, another hole appears in the hull. You patch what you can with courage, prayer, and community, and you keep rowing, no matter how fast the hurricane is approaching.

Note: Huntington’s Disease News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. The opinions expressed in this column are not those of Huntington’s Disease News or its parent company, Bionews, and are intended to spark discussion about issues pertaining to Huntington’s disease.